Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India (SPOTLIGHT)

NCT05020873 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05020873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05020873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India (SPOTLIGHT)
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Terminated
Start date
November 4, 2021
Completion date
August 31, 2023
Enrollment
44 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease